Veterinary Product Information
Vet > Fevaxyn FeLV

Fevaxyn FeLV

This page contains information on Fevaxyn FeLV for veterinary use.
The information provided typically includes the following:
  • Fevaxyn FeLV Indications
  • Warnings and cautions for Fevaxyn FeLV
  • Direction and dosage information for Fevaxyn FeLV

Fevaxyn Felv

This treatment applies to the following species:
Manufacturer: Schering-Plough

Feline Leukemia Vaccine

Killed Virus

For veterinary use in cats only

Product Description

Fevaxyn® FeLV vaccine is recommended for the vaccination of healthy cats as an aid in the prevention of lymphoid tumors caused by, and diseases associated with, feline leukemia virus (FeLV) infection. Vaccination with this product prevents persistent viremia in cats exposed to virulent feline leukemia virus.

Fevaxyn FeLV vaccine contains a tissue culture derived feline leukemia virus, Subgroups A and B. The virus has been chemically inactivated and combined with a proprietary adjuvant designed to enhance the immune response.

Fevaxyn FeLV Dosage And Administration

Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.

Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.

Two doses are required for primary immunization.

Annual revaccination with one dose is recommended.

Allow The Vaccine To Warm To Room Temperature Prior To Use. Shake Well Before Use.

Precautions

Store at 2°-7°C.

Do not freeze.

Do not mix with other vaccines.

Use new, non-chemically sterilized needles and syringes.

Warnings

Contains gentamicin and amphotericin B as preservatives.

Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.

The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions.

Antidote

Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

It is important to realize that certain conditions and events may cause some cats to be unable to develop or maintain an adequate immune response following vaccination. Prior exposure to the disease, or disease latency, are conditions in which vaccination will not alter the course of the disease. Therefore, diagnostic testing of all cats for FeLV antigen prior to vaccination is recommended. Also, vaccination with this product will not offer cross-protection against feline immunodeficiency (FIV), another feline retrovirus. It is important to advise the cat owner of these situations prior to vaccination.

U.S. Veterinary License No. 165A

Schering-Plough Animal Health Corporation, Omaha, NE 68103 USA

1 800 224-5318 (USA)

1 888 306-0069 (Canada)

© 1999, 2001, 2006, Schering-Plough Animal Health Corp.

All rights reserved.

 

NDC-

 

25x1 DOSE

0061-1419-03

P20002-12

50x1 DOSE

0061-1419-01

P20004-11

Nac No.

10470723
SCHERING-PLOUGH ANIMAL HEALTH CORPORATION
556 MORRIS AVE., SUMMIT, NJ, 07901
Telephone:   908-629-3490
Order Desk:   800-648-2118
Fax:   908-629-3306
Customer Service:   800-521-5767
Website:   www.sp-animalhealth.com
Every effort has been made to ensure the accuracy of the Fevaxyn FeLV information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.



Advertisement

(web4)